Phase I Clinical and Plasma and Cellular Pharmacological Study of Topotecan without and with Granulocyte Colony-stimulating Factor

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1489-1497

  Abbruzzese, James L ^a,b   Madden, Timothy ^a   Sugarman, Steven M ^a   Ellis, Amy L ^a   Loughlin, Susan ^a   Hess, Kenneth R ^a   Newman, Robert A ^a   Zwelling, Leonard A ^a   Raber, Martin N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CYTOLOGY; DIARRHEA; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NAUSEA; NEOPLASM; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DIARRHEA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUTROPENIA; SKIN DISEASES; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME; VOMITING;

EID: 0030223030     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Kingsbury, W. D , Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., and Johnson, R. K. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
2. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Ann. Rev Biochem., 58: 351-375, 1989.
3. Jaxel, C., Kohn, K W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
4. Chen, A. Y., and Liu, L F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
5. Johnson, R. K. Hertzberg, R. P., Kingsbury, W. D., Boehm, J. C., Caranfa, M. J., Faucette, L. F., McCabe, F. L., and Holden, K. G. Preclmical profile of SK and F 104864, a water-soluble analog of camptothecin. Proceedings of the Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, p. A301 National Cancer Institute-EORTC, 1989.
6. Johnson, R. K., McCabe, F L., Gallagher, G., Wood, J., Galef, J., and Hertzberg, R. P. Comparative efficacy of topotecan, irinotecan, camptothecin, and 9-aminocamptothecin in preclinical tumor models. Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam. Ann. Oncol., 3 (Suppl. 1): 85, 1992.
7. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
8. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forasterie, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kauffman, S. H., and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin. Oncol., 10: 647-656, 1992.
9. Verweij, J., Lund, B., Beijnen, J., Planting, A., de-Boer-Dennert, M., Koier, I., Rosing, H., and Hansen, H. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 4: 673-678, 1993.
10. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
11. Saltz, L., Sirott, M., Young, C., Tong, W., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B., Wright, P., Barbarosa, K., Toomasi, F., and Kelsen, D. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst., 85: 1499-1507, 1993.
12. Rowinsky, E. K., Sartorius, S., Grochow, L., Forastiere, A., Lubejko, B., Hurowitz, L., and Donehower, R. Phase I and pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor toxocologic differences between concurrent and post-treatment G-CSF administration. Proc. Am. Soc. Clin. Oncol. Annu. Meet , 11: 116, 1992.
13. Wanders, J., Ardizzoni, A., Hansen, H. H., Dombernowsky, P., Postmus, P. E., Buitenhuis, M., McDonald, M., Giaccone, G., and Verweij, J. Phase II study of topotecan in refractory and sensitive small cell lung cancer Proc. Am. Assoc. Cancer Res , 36: 327, 1995.
14. Kudelka, A., Edwards, C., Freedman, R., Wallin, B., Hord, M., Howell, E., Harper, K., Raber, M., and Kavanaugh, J. An open Phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Am. Soc. Clin. Oncol., 12: 259, 1993.
15. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995
16. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell-killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
17. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
18. Madden, K R., and Champoux, J. J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res., 52: 525-532, 1992.
19. Sugimoto, Y., Tsukahara, S., Ohhara, T., Isoe, T., and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50: 6925-6930, 1990.
20. Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E , Hertzberg, R. P., Caranfa, M. J., and Johnson R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerace I. Cancer Res., 48: 6404-6410, 1988.
21. Ajani, J. A., Abbruzzese, J. L., Goudeau, P., Faintuch, J., Yeomans, A , Boman, B., and Levin, B. Ifosfamide and mesna: marginally active in patients with cancer of the pancreas. J. Clin. Oncol., 6: 1703-1707, 1988.
22. National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD. National Cancer Institute, 1988.
23. Coombs, D. H., and Pearson, G. D. Filter binding assay for covalent DNA-protein complexes: adenovirus DNA-terminal protein complex. Proc. Natl. Acad. Sci. USA, 75: 5291-5295, 1978.
24. Thomas, C. A., Saigo, K., McLeod, E., and Ito, J. The separation of DNA segments attached to proteins. Anal. Biochem., 93: 158-166, 1979.
25. Shin, C. G., Strayer, J. M., Wani, M. A., and Snapka, R. M. Rapid evaluation of topoisomerase inhibitors: caffeine inhibiton of topoisomerases in vivo. Teratog. Carcinog. Mutagen., 10: 41-52, 1990.
26. Higgins, N. P., and Cozzarelli, N. R The binding of gyrase to DNA: analysis by retention by nitrocellulose filters. Nucleic Acids Res., 10: 6833-6847, 1982.
27. Houck, C. M., Rinehart, F. P., and Schmid, C. W. A ubiquitous family of repeated DNA sequences in the human genome. J. Mol. Biol., 132: 289-306, 1979.
28. Ellis, A. L , Nowak, B., Plunkett, W., and Zwelling, L. A. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother. Pharmacol., 34: 249-256, 1994.
29. Van Warmerdam, L. J. C., ten Bokkel Huinink, W. W., Rodenhuis, S., Koier, I., Davies, B. E., Rosing, H., Maes, R. A. A., and Beijnen, J. H. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-h continuous infusion. J. Clin. Oncol., 13: 1768-1776, 1995.
30. Blaney, S. M., Balls, F. M., Cole, D. E., Craig, C., Reid, J. M., Ames, M. M., Krailo, M., Rearman, G., Hammond, D., and Poplack, D. G. Pediatric Phase I trial and pharmacokinetic study of topotecan administered as a 24-h continuous infusion. Cancer Res., 53: 1032-1036, 1993.
31. Kantarjian, H. M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S , Cazenave, L., Koller, C., Rios, M. B., Plunkett, W., Keating, M. J., and Estey, E. H. Phase I study of topotecan, a new topoisomerase inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 81: 1146-1151, 1993.
32. Eng, W-K., Faucette, L., Johnson, R. K., and Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 34: 755-760, 1988.
33. Bjornsti, M-A., Benedetti, P., Vigianti G. A , and Wang, J. C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res., 49, 6318-6323, 1989.
34. Subramanian, D., Kraut, E., Staubus, A , Young, D. C., and Muller, M T Analysis of topoisomerase I/DNA complexes in patients administered topotecan Cancer Res., 55: 2097-2103, 1995.
35. Husain, I., Monier, J. L., Seigler, H. F , and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54: 539-546, 1994.
36. Reed, E., Yuspa, S. H., Zwelling, L. A., Ozols, R. A., and Poirier, M C. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J. Clin. Invest., 77: 545-550, 1986.
37. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J. Clin. Oncol., 13: 2301-2308, 1995.
38. Kaufmann, S. H., Charron, M., Burke, P. J , and Karp, J. E. Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo. Cancer Res., 55: 1255-1260, 1955.
39. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J., Burke, P. J., Cheng, Y-C., Grochow, L. B., and Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol . 12: 2193-2203, 1994.